Kyverna Therapeutics, Inc. · NASDAQ:KYTX

Kyverna Therapeutics — Technical Presentation (November 2024)

17 slides from Kyverna Therapeutics's technical presentation, November 2024

  1. Slide 1: Comprehensive Immune Profiling of Anti-CD19 CAR T-Cell Therapy in Patients with Autoimmune Disease

    Comprehensive Immune Profiling of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Patients with Autoimmune Disease Justin Chou1, Ricardo Grieshaber-Bouyer2,3, Michelle J Wu4, Christina Bergmann2,3, Jule Taubmann3, Fabian Müller3,5, Aline Bozec2,3, Tobias Rothe2,3, Andreas Mackensen3,5, Amber P

  2. Slide 2: Disclosures

    Disclosures • Justin Chou, Francis Kim, Prameela Ramesan, Brandon Kwong, Kunbin Qu, Bishwa Ganguly, Dominic Borie, and James Chung are employees of Kyverna Therapeutics, Inc with stock/stock options. • Ricardo Grieshaber-Bouyer has received funding from Kyverna Therapeutics, Inc. • Michelle J Wu, Ga

  3. Slide 3: Disclaimer and Forward-Looking Statements

    Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management of Kyverna Therapeutics, Inc. (“Kyverna”, “we”, “our,” or the “Company”). All statements other t

  4. Slide 4: CAR T-Cell Therapy: Transformative Potential for Patients With B-Cell Driven Autoimmune Diseases

    CAR T-Cell Therapy Transformative Potential for Patients With B-Cell Driven Autoimmune Diseases Unmet CAR T-cell Transformative Medical Therapy Patient Needs Approach Outcomes • Tissue-resident pathogenic • Cell therapy targets a diverse • Paradigm changing, single B cells are central to array of ti

  5. Slide 5: Characteristics of Patients with Autoimmune Disease and Healthy Donors

    Characteristics of Patients with Autoimmune Disease and Healthy Donors Analyzed Samples Patients with Autoimmune LN MG SSc 1 SSc 2 IIM 1 IIM 2 Disease (n=6) CAR construct KYV-101 KYV-101 MB-CART19.1 MB-CART19.1 MB-CART19.1 MB-CART19.1 Dose 5×107 1×108 1×106/kg 1×106/kg 1×106/kg 1×106/kg Weight, kg 1

  6. Slide 6: A Multi-Omics Approach to Analyzing Immune Cell Subsets

    A Multi-Omics Approach to Analyzing Immune Cell Subsets Verily Immune Profiler Schematic workflow 24 immune cell subsets Myeloid Cells Monocytes Dendritic cells MoCl (Classical) coDC (Conventional) MoIn (Intermediate) plDC (Plasmacytoid) MoNC (Nonclassical) T cells CD4 T cells CD8 T cells γδ T cells

  7. Slide 7: Expected Cell-Type Specific Gene Expression Confirmed in Each Immune Cell Subset

    Expected Cell-Type Specific Gene Expression Confirmed in Each Immune Cell Subset Platform Verification Unsupervised gene clustering from RNA-seq depicts specific expression across subsets, including verification of well-known lineage-specific transcription factors and cellular identity markers1 Log1

  8. Slide 8: Distinct Immune Cell Clusters Identified by tSNE Analysis

    Distinct Immune Cell Clusters Identified by tSNE Analysis Platform Verification tSNE visualization of RNA-seq data shows clustering of immune cell types Myeloid cells Monocytes Dendritic cells MoCl coDC NK cells MoIn plDC 20 MoNC T cells CD8 T cells CD4 T cells CD8 T cells γδ T cells Myeloid cells T

  9. Slide 9: CAR T-cell Therapy Alters Relative Proportions of Immune Cell Subsets

    CAR T-cell Therapy Alters Relative Proportions of Immune Cell Subsets Fluorescence Activated Cell Sorting from PBMCs Immune reset supported by shift from memory to transitional B cells Increase in CD56hi NK cells and decrease in naïve T cells observed in the periphery post-CAR T-cell therapy 1e+02 S

  10. Slide 10: Global Changes in Immune Cell Profiles Post-CAR T-cell Therapy

    Global Changes in Immune Cell Profiles Post-CAR T-cell Therapy Differentially accessible regions are Naïve T cells, gamma delta T cells, and CD56low NK Tregs show the greatest number of identified in all cell types cells show more differentially expressed genes differentially expressed proteins ATAC

  11. Slide 11: Downregulation of Autoimmune Drivers and Evidence of Epigenetic Changes Across Immune Cell Types

    Downregulation of Autoimmune Drivers and Evidence of Epigenetic Changes Across Immune Cell Types RNA-Seq of Sorted Immune Cell Subsets Downregulation of gene ontologies associated with global gene expression and mechanisms of autoimmunity Immune Cell Subset • Downregulation of DNA/RNA binding sugges

  12. Slide 12: Signs of Improved Immune Tolerance through Enhancement of Regulatory T cells

    Signs of Improved Immune Tolerance through Enhancement of Regulatory T cells TaPE-Seq: Protein Expression in Tregs Treg inhibitory proteins are significantly increased post-treatment to a level comparable to healthy donors Upregulated HD_1−Baseline HD-1 Pre-CAR Healthy T cell AID Donors HD_2−Baselin

  13. Slide 13: Innate Immune-Mediated Inflammation May Be Alleviated Post-CAR T-cell Therapy

    Innate Immune-Mediated Inflammation May Be Alleviated Post-CAR T-cell Therapy TaPE-Seq: Protein Expression in Nonclassical Monocytes Siglec-1 and granulocytic lineage marker proteins are downregulated post-treatment to a level similar to healthy donors Downregulated • Downregulation of Siglec-1 Sigl

  14. Slide 14: Immune Reset Suggested by Overall Shift Towards Healthy Donor Gene Expression Profile

    Immune Reset Suggested by Overall Shift Towards Healthy Donor Gene Expression Profile RNA-Seq Across All Immune Cell Subsets Principal component analysis of gene expression in paired pre- and post-patient samples compared to healthy volunteers (LN) (IIM-2) Timepoint Healthy volunteers (MG) Pre-CAR T

  15. Slide 15: CAR T-cell Therapy May Achieve Immune Reset by Broadly Modulating the Immune Landscape

    CAR T-cell Therapy May Achieve Immune Reset by Broadly Modulating the Immune Landscape Multiple potential mechanisms of immune reset were identified Deep B-cell depletion • CAR T-cell therapy can drive the leading to immune reset immune system of patients with Enhanced tolerogenic cells autoimmune d

  16. Slide 16: Acknowledgements

    Acknowledgements • We would like to thank the patients and healthy donors who donated their cells for this work • We thank Elizabeth Wheatley for writing support sponsored by Kyverna Therapeutics, Inc, and Ramona Pufan and Ashley Mahne (Kyverna Therapeutics, Inc) for invaluable editing assistance of

  17. Slide 17: Thank You Q&A

    THANK YOU Q&A 17 For purposes of scientific exchange only. All therapies are investigational.

Kyverna Therapeutics — Technical Presentation (November 2024) on 6ix